Abingworth LLP
- SEC CIK
- 0001397144
- Latest filing
- Feb 10, 2023
Holdings in Q3 2021
Holdings as of Sep 30, 2021, filed Nov 15, 2021. Long positions only; changes compare share counts with Q2 2021.
- Positions
- 20
- +1 vs. Q2 2021
- Portfolio value
- $440.7M
- +$117.2M (+36.2%) vs. Q2 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| OCGNOcugen, Inc. | Common | 7,111 | $51.0K | <0.1% | 00.0% | Unchanged | History |
| OBSVObsEva SA | COM | 87,999 | $274.0K | 0.1% | 00.0% | Unchanged | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 131,036 | $478.0K | 0.1% | 00.0% | Unchanged | History |
| MTEMMolecular Templates, Inc. | COM | 200,000 | $1.34M | 0.3% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM | 240,500 | $1.91M | 0.4% | 00.0% | Unchanged | History |
| PRTKParatek Pharmaceuticals, Inc. | COM | 1,041,131 | $5.06M | 1.1% | 00.0% | Unchanged | History |
| XCURExicure, Inc. | COM | 6,977,000 | $8.23M | 1.9% | 00.0% | Unchanged | History |
| NCNANuCana plc | SPONSORED ADR | 3,333,333 | $8.57M | 1.9% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM NEW | 10,302,602 | $9.50M | 2.2% | 00.0% | Unchanged | History |
| Spruce BioE5209E109 | Common | 1,792,518 | $10.7M | 2.4% | 00.0% | Unchanged | – |
| ACETAdicet Bio, Inc. | COM | 1,615,385 | $12.6M | 2.9% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 2,457,499 | $13.4M | 3.0% | 00.0% | Unchanged | History |
| SIENProject Sage Oldco, Inc. | COM | 2,349,827 | $13.5M | 3.1% | −41,016−1.7% | Reduced | History |
| OKUROnKure Therapeutics, Inc. | COM | 2,073,957 | $15.3M | 3.5% | +111,736+5.7% | Added | History |
| SRRASierra Oncology, Inc. | COM | 876,656 | $19.0M | 4.3% | +5,531+0.6% | Added | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,203,135 | $38.5M | 8.7% | 00.0% | Unchanged | History |
| VERAVera Therapeutics, Inc. | CL A | 2,960,231 | $51.4M | 11.7% | 00.0% | Unchanged | History |
| JSPRJasper Therapeutics, Inc. | COM | 5,628,558 | $58.0M | 13.2% | +5,628,558 | New | History |
| EFTReFFECTOR Therapeutics, Inc. | COM | 4,822,114 | $67.0M | 15.2% | +4,822,114 | New | History |
| PCVXVaxcyte, Inc. | COM | 4,168,718 | $105.8M | 24.0% | 00.0% | Unchanged | History |
Sold out since Q2 2021 (1)
Positions held at the end of Q2 2021 that are gone from this filing.